Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo biomarcador multifuncional para el cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20190221001
Publicado:
27/03/2019
Caducidad:
27/03/2020
Resumen:
Un grupo de investigación alemán ha demostrado la relación entre el dominio de trombospondina tipo 1 que contiene la proteína 7A (THSD7A) y varios tipos de cánceres y ofrece una nueva forma de utilizar este tumor específico para mejorar la eficacia del tratamiento oncológico mediante un diagnóstico precoz. Debido a la fuerte relación con varias entidades tumorales, la THSD7A puede considerarse un biomarcador robusto y multifuncional, siendo una herramienta valiosa para medicina personalizada en el tratamiento del cáncer y mejorando directamente el cuidado del paciente con un diagnóstico precoz de la enfermedad y un mejor ajuste de las medidas terapéuticas. El grupo de investigación busca socios industriales e institucionales especializados en el desarrollo y producción de biomarcadores del cáncer, diagnóstico/terapia del cáncer e investigación del tratamiento con el fin de establecer acuerdos de licencia, transferencia de derechos, transferencia de conocimiento o cooperación en materia de I+D.

Details

Tittle:
A novel and multifunctional biomarker for cancer
Summary:
A German research team has demonstrated the link between Thrombospondin Type-1 Domain containing 7A Protein and various cancer types and presents a new way to use this tumor specific to improve cancer treatment efficiency by early diagnosis. Sought are industrial or institutional partners involved in the development and/or production of cancer biomarkers, cancer diagnosis/therapy, and research of cancer treatment for licensing, transfer of rights, knowledge transfer, or R-Y-D cooperation.
Description:
The timely medical diagnosis of cancer requires biomarkers which are specific for the different cancer types.

A German research group has revealed a direct link between specific tumor entities and the expression level of Thrombospondin Type-1 Domain containing 7A protein (THSD7A), which can be utilized as a new tumor antigen to increase the predictive value of in-vitro diagnostic and prognostic detection methods for cancer, leading to an optimized early diagnosis and treatment decision.

Immunohistochemistry tests using tissue microarrays were performed on more than 70 tumor entities (including 20.000 tissue spots) and have demonstrated the association between the THSD7A marker and the described tumor entities, e.g. for breast, prostate, renal, and colorectal cancer. Furthermore, THSD7A antibodies are measurable in whole blood, serum, or plasma. This combination makes it a powerful screening tool for tumor identification. For example, in case of the renal disorder Membranous Nephropathy (MN), a concomitant malignancy could be indicated by the presence of THSD7A antibodies.

Additionally, the innovation offers the possibility to treat THSD7A expressing cancer cells selectively with cytotoxic compounds linked to anti-THSD7A antibodies to optimize site directed drug application and minimize therapeutic side effects.

Due to the strong relation to several tumor entities, THSD7A can be considered a robust and multifunctional biomarker making it a helpful tool for personalized medicine in cancer treatment, which shall directly improve patient care through early diagnosis of the disease and better adjustment of therapeutic measures.

Partners could be enterprises or institutions involved in the development and/or production of cancer biomarkers, cancer diagnosis and therapy, research in cancer treatment, Membranous Nephropathy, or in personalized medicine. They could benefit from a transfer of rights of the existing IP (patent pending), licensing, knowledge transfer, or R-Y-D collaborations to test and refine the technology in commercially relevant projects.
Advantages and Innovations:
The advantages of the invention for tumor screening lies in the combination of easy detection of THSD7A antibodies in serum, plasma, or (whole) blood, and its expression in different relevant neoplasias, e.g. breast, prostate, renal, or colorectal cancer.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
PCT-application filed

Partner sought

Type and Role of Partner Sought:
Sought are industrial or institutional partners involved in the development and/or production of cancer biomarkers, cancer diagnosis and therapy, research of cancer treatment, Membranous Nephropathy, or in personalized medicine.

Partners are sought for licensing, transfer of rights (pending patent), or knowledge transfer. The innovation could be tested and refined in commercially relevant projects and R-Y-D cooperation.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
German

Keywords

Technology Keywords:
01004001 Applications for Health
06001005 Diagnósticos, diagnosis
03004007 Pharmaceutics